Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188188 | 1.00 | MEN1 (0.53) | MEN1KMT2AADRB3ADRB1ADRB2 | |
| SCHEMBL16788643 | 0.84 | L3MBTL1 (0.49) | MEN1KMT2AADRB3ADRB1ADRB2 | |
| SCHEMBL15590888 | 0.84 | L3MBTL1 (0.49) | MEN1KMT2AADRB3ADRB1ADRB2 | |
| SCHEMBL14691472 | 0.84 | MEN1 (0.54) | MEN1KMT2AACP3CYP1A2CYP2D6 | |
| SCHEMBL8869652 | 0.82 | MEN1 (0.56) | MEN1KMT2AACP3CTSA | |
| SCHEMBL28520767 | 0.81 | ADRB2 (0.50) | ADRB3ADRB1ADRB2 | |
| SCHEMBL8771026 | 0.81 | GABBR2 (0.42) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1198080 | 0.81 | KMT2A (0.55) | MEN1KMT2AACP3CYP1A2CYP2D6 | |
| SCHEMBL20535150 | 0.81 | ALDH1A1 (0.58) | MEN1KMT2AADRB3ADRB1ADRB2 | |
| SCHEMBL30861879 | 0.81 | KMT2A (0.55) | MEN1KMT2AACP3CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702157-A1 | ACYL-TRNA SYNTHETASES | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | claimed |
| WO-2024223922-A1 | ACYL-tRNA SYNTHETASES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-10-31 | — | — | WO | claimed |
| CN-115537405-B | Ketoreductase and application thereof in preparation of (S) -1- (3-chlorophenyl) -1, 3-propanediol | 尚科生物医药（上海）有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-115537405-A | Ketoreductase and application thereof in preparation of (S) -1- (3-chlorphenyl) -1, 3-propylene glycol | 尚科生物医药（上海）有限公司 | 2022-12-30 | — | — | CN | claimed |
| EP-4702157-A1 | ACYL-TRNA SYNTHETASES | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024223922-A1 | ACYL-tRNA SYNTHETASES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-10-31 | — | — | WO | disclosed |
| CN-108863797-A | The preparation method of a kind of 3- (substitution/unsubstituted phenyl) -3- hydroxyl propionyl hydroxamic acid | 吉首大学 | 2018-11-23 | — | — | CN | disclosed |
| EP-1504014-B1 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | METABASIS THERAPEUTICS INC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2223927-B1 | Salts of a phosphonic acid based prodrug of PMEA | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| CN-1964967-B | Lewis acid mediated synthesis of cyclic esters | METABASIS THERAPEUTICS INC | 2014-04-16 | — | — | CN | disclosed |
| EP-1753762-B1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-1556393-B1 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2004041834-A2 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030225277-A1 | Process for preparation of cyclic prodrugs of PMEA and PMPA | METABASIS THERAPEUTICS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003095665-A2 | PMEA AND PMPA CYCLIC PRODUCING SYNTHESIS | METABASIS THERAPEUTICS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| EP-0451668-B1 | Process for the production of optically active alkyl 3-aryl-3-hydroxypropionates | CHISSO CORP (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5202457-A | Enzyme catalyzed transesterification, resolution of optical active alkyl 3-aryl-3-hydroxypropionate | CHISSO CORPORATION (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0451668-A2 | Optically active alkyl 3-aryl-3-hydroxypropionates and a method for producing thereof | CHISSO CORPORATION (JP) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225277-A1 | Process for preparation of cyclic prodrugs of PMEA and PMPA | MPO, PNP, MAOA | MEN1 871/4885KMT2A 458/4885ADRB3 2909/4885 |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | MEN1 922/4885KMT2A 585/4885ADRB3 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.